INC Research, LLC, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, is the lead sponsor of FierceBiotech’s Fierce Clinical Insights Executive Breakfast on Wed., Apr. 13, from 7:30 a.m. – 9:00 a.m., held at the Hotel Nikko in San Francisco.

Executives from Pfizer, the Gladstone Institute of Cardiovascular Disease, Theravance, Calithera Biosciences, and Exelixis will be discussing the issues facing today’s drug developers as they attempt to design and execute an ideal Phase II clinical trial. The unique format of the event will give attendees an opportunity to exchange their ideas with top industry executives about the latest trends and technologies being applied in mid-stage studies. John Carroll, executive editor of FierceBiotech, will be moderating the
expert panel.

For most biotechs, Phase II remains right at the crossroads of success and failure. Getting there and navigating all the pitfalls that await any developer in the process is crucial to obtaining critical proof of concept data. This event will provide valuable insight for biotechs looking for new ways to improve their odds of success in leading them to the threshold of Phase III and the best possible alliance for their lead products.